On May 29, 2025, Oppenheimer analyst Andreas Argyrides released an update on InflaRx (IFRX, Financial), maintaining an "Outperform" rating while lowering the price target from $6.00 to $3.00. This adjustment represents a 50% decrease in the price target.
The decision to maintain the "Outperform" rating indicates continued confidence in InflaRx's potential market performance despite the significant reduction in the price target. The price target change reflects a measured approach to the company's valuation, considering current market conditions and potential future developments.
Investors in InflaRx (IFRX, Financial) should note the revised price target and maintain awareness of ongoing analyst evaluations as market dynamics evolve.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for InflaRx NV (IFRX, Financial) is $6.81 with a high estimate of $12.91 and a low estimate of $1.99. The average target implies an upside of 730.52% from the current price of $0.82. More detailed estimate data can be found on the InflaRx NV (IFRX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, InflaRx NV's (IFRX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
